---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-383645"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2026-09-04T20:06:30+00:00"
generated_at: "2026-09-04T20:07:10.948671+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Intellia secures $400M non-dilutive credit facility with OrbiMed; $75M funded upfront

## Summary
- $75M funded at closing; up to $325M additional tied to milestones (FDA approval of lonvo-z, revenue targets, equity raise, mutual agreement).
- Interest at SOFR + 6.15% (3% floor), maturity Sept 4, 2031; secured by substantially all assets incl. IP.
- Proceeds for working capital and general corporate purposes; covenants include maintaining $50M liquidity until FDA approval of lonvo-z.
- Facility provides flexibility for lonvo-z launch in HAE and pipeline advancement; TD Cowen advised Intellia.

## SEC filing metadata
- accession: 0001193125-26-383645
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2026-09-04T20:06:30+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312526383645/0001193125-26-383645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312526383645/d110798d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-383645
- JSON: https://secwatch.observer/filing/0001193125-26-383645.json
- Plain text: https://secwatch.observer/filing/0001193125-26-383645.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.